IDEXX Laboratories, Inc. — FY2012 Form 10-K Summary
Business context and reporting period
IDEXX develops diagnostic products, information technology systems and services for veterinary, bioresearch, livestock and poultry, water-quality, dairy and human point-of-care markets. The filing covers the fiscal year ended December 31, 2012, with comparative results for 2011 and 2010. Reportable segments were Companion Animal Group (CAG), Water, Livestock and Poultry Diagnostics (LPD), and Other.
Key financial metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $1,293.3 million | $1,218.7 million | 6.1% increase |
| Gross profit | $699.1 million | $646.5 million | 8.1% increase |
| Gross margin | 54.1% | 53.0% | Up 1.1 percentage points |
| Operating income | $262.6 million | $236.2 million | 11.1% increase |
| Operating margin | 20.3% | 19.4% | Up 0.9 percentage points |
| Net income attributable to IDEXX stockholders | $178.3 million | $161.8 million | 10.2% increase |
| Diluted EPS | $3.17 | $2.78 | 14.0% increase |
| Net cash from operating activities | $230.3 million | $220.7 million | 4.3% increase |
| Capital expenditures | $65.5 million | $52.5 million | Increase |
| Cash and cash equivalents | $224.0 million | $183.9 million | Increase |
| Total debt | $214.5 million | $246.4 million | Decrease |
Product revenue was $817.0 million and service revenue was $476.3 million. The company’s consolidated revenue reductions for customer programs increased to $42.3 million from $33.2 million, including higher up-front loyalty and instrument marketing incentives.
Segment performance and material changes
- CAG: Revenue increased 7.3% to $1,072.2 million, with organic growth of 7.5%. Reference laboratory services increased 8.9%, VetLab consumables increased 9.0%, rapid assays increased 5.1%, and practice-management and digital-imaging revenue increased 11.3%. VetLab instrument revenue declined 3.7%, primarily due to lower Catalyst Dx and LaserCyte sales and greater use of reagent-rental arrangements, under which instrument revenue is deferred.
- Water: Revenue increased 3.1% to $84.7 million, driven primarily by higher Colilert sales volumes. Operating margin increased to 44.5% from 41.2%.
- LPD: Revenue decreased 7.9% to $86.7 million and operating income decreased 18.9% to $19.3 million. Results were affected by lower bovine testing demand, changes in European Union BSE testing requirements and declines in certain government programs. BSE product revenue was less than $10 million.
- Other: Revenue increased 16.4% to $49.7 million, mainly from higher Dairy testing and OPTI Medical sales. Results included a $3.5 million milestone payment related to the prior sale of pharmaceutical product rights.
- Foreign-exchange movements reduced 2012 revenue by approximately $19.0 million, primarily because of a stronger U.S. dollar. Approximately 41% of total revenue was attributable to customers outside the United States.
- Research and development expense increased to $82.0 million from $76.0 million, while sales and marketing expense increased to $217.0 million from $204.9 million.
- The company repurchased 1.47 million shares for $132.3 million during 2012, compared with 3.42 million shares for $255.5 million in 2011. IDEXX has never paid a cash dividend and stated that it had no present intention to do so.
Cash flow, liquidity and debt
- Operating cash flow was $230.3 million. Investing cash flow used $66.0 million, including $65.5 million of property and equipment purchases and $2.7 million of cash acquisitions. Financing cash flow used $125.3 million, including share repurchases and $31.0 million of net repayments under the revolving credit facility.
- At December 31, 2012, $212.0 million was outstanding under the $300 million unsecured revolving credit facility, leaving approximately $87 million of borrowing availability after the letter-of-credit reduction. The facility matures July 25, 2016.
- The company was in compliance with the facility’s covenants, including a consolidated leverage ratio not exceeding 3-to-1. Borrowings had a weighted-average effective interest rate of 1.3%.
- Management stated that cash on hand, operating cash flow and available borrowings were expected to fund operations, capital requirements and strategic growth needs for at least the next twelve months.
- Projected 2013 capital expenditures were approximately $75 million, including $21 million for headquarters expansion, $16 million for software and information technology, $12 million for manufacturing equipment and $10 million for reference laboratory facilities and equipment.
- Approximately $222.4 million of cash was held by foreign subsidiaries and was subject to material potential repatriation tax effects. The company considered most foreign subsidiary earnings indefinitely invested outside the United States.
Guidance, outlook, risks and unusual items
- Management was cautiously optimistic that improving U.S. economic conditions and patient-visit trends could gradually reduce pressure on demand, but European economic conditions remained challenging.
- Management anticipated lower 2013 Dairy sales of Aflatoxin M1 tests because 2012 testing in China was elevated by an outbreak response.
- The American Taxpayer Relief Act retroactively reinstated the federal R&D tax credit for 2012 and 2013. IDEXX expected this to reduce its 2013 effective tax rate by approximately two percentage points versus 2012.
- A Federal Trade Commission consent agreement, finally approved February 11, 2013, resolved an investigation into distribution and marketing practices. The ten-year agreement limits IDEXX to exclusive distribution agreements with two of three specified major distributors. The company modified its MWI agreement effective January 1, 2013 and expected lower compensation to MWI, with savings reinvested in sales and marketing.
- Key risks include intense competition and technological change; dependence on sole- or single-source suppliers; regulatory approvals and compliance; economic sensitivity of veterinary and government-funded testing demand; foreign-currency exposure; distributor concentration and purchasing variability; dependence on patents and licenses; facility or information-system interruptions; and potential changes in testing regulations.
- Contractual cash obligations totaled $206.3 million, including $70.9 million of operating leases, $128.0 million of purchase obligations and $4.8 million of minimum royalty payments. The company also disclosed contingent commitments of up to $7.5 million related primarily to an acquired intangible asset, not accrued because they were not considered probable.
- Goodwill and intangible-asset impairment testing identified no impairments. The company reduced the estimated useful lives of certain OPTI Medical intangible assets, increasing amortization in the fourth quarter of 2012 and future periods; management did not expect a material financial impact.
- PricewaterhouseCoopers LLP issued an unqualified opinion on the consolidated financial statements and internal control over financial reporting. Management concluded that internal controls were effective as of December 31, 2012.
Important facts for investors to verify
- Whether CAG consumable and reference-laboratory growth continues to offset lower instrument revenue and customer incentives.
- The effect of the FTC distribution restrictions and the modified MWI relationship on competitive positioning, sales-force effectiveness and margins.
- LPD’s continuing exposure to European BSE-testing changes, government programs and foreign currency.
- Execution of the approximately $75 million 2013 capital-expenditure plan and headquarters expansion.
- Availability and pricing of critical supplies from sole- and single-source vendors, including Ortho chemistry slides and other proprietary consumables.
- Cash accessibility and potential tax costs associated with repatriating foreign-held cash and undistributed earnings.
- Compliance with the revolving credit facility’s covenants and sensitivity to interest rates, foreign exchange and operating performance.
- The sustainability of reported earnings growth after excluding the $3.5 million pharmaceutical milestone payment and other unusual items.